Breakthrough Clinical Results
A new study published in Cancer Diagnosis & Prognosis shows that Castle Biosciences' DecisionDx-Melanoma test surpasses both American Joint Committee on Cancer (AJCC) staging and the CP-GEP test in identifying low-risk melanoma patients. The DecisionDx-Melanoma test demonstrated a 2.8% sentinel lymph node (SLN) positivity rate in low-risk patients, significantly lower than the 5% threshold recommended by the National Comprehensive Cancer Network (NCCN) guidelines for forgoing sentinel lymph node biopsy (SLNB) surgery. This improved accuracy allows for better risk stratification and more informed decisions regarding SLNB, potentially avoiding unnecessary surgery for low-risk patients. The study highlights the test's ability to improve clinical decision-making and patient outcomes.
Key Highlights
- DecisionDx-Melanoma outperforms AJCC staging and CP-GEP in identifying low-risk melanoma patients.
- Patients identified as low-risk by DecisionDx-Melanoma had a 2.8% SLN positivity rate, below the NCCN 5% threshold for forgoing SLNB surgery.
- The study confirms DecisionDx-Melanoma's accuracy in identifying patients with minimal risk of metastasis.
- Results support the use of DecisionDx-Melanoma to guide SLNB decisions, improving patient care and reducing unnecessary procedures.
Incidence and Prevalence
Global Melanoma Incidence and Prevalence: Recent Estimates and Trends
Several studies provide recent estimates of melanoma incidence and prevalence globally, with some variation in the reported figures depending on the data source and year. Here's a summary of the most recent findings:
Incidence:
- 2020: A study evaluating global incidence and mortality rates reported an age-standardized incidence rate of 3.4 per 100,000 worldwide. Another study estimated a total of 325,000 new melanoma cases worldwide in 2020 (174,000 males, 151,000 females).
- 2021: The Global Burden of Disease 2021 study reported a substantial global increase in melanoma incidence, but did not provide a specific age-standardized rate for this year. Another study using the same database reported 289,950 incident cases of melanoma globally in 2019, with the age-standardized incidence rate increasing by an average of 1.13% annually from 1990 to 2019.
- 2022: GLOBOCAN 2022 data indicated that melanoma was the 17th most common cancer globally, with an estimated 331,722 new cases diagnosed and approximately 58,667 deaths.
Prevalence:
- 2019: A study using the Global Burden of Disease 2019 study estimated the global prevalence of melanoma, but did not provide a specific age-standardized rate.
- 2021: A study analyzing melanoma trends in the US using the US Cancer Statistics database reported a 20-year limited duration prevalence of 0.279 (95% CI: 0.276-0.282). Males showed a higher prevalence (0.302) compared to females (0.256).
Trends:
Most studies indicate an increasing trend in melanoma incidence globally, particularly in older age groups and males. This increase may be attributed to factors such as improved healthcare infrastructure, better cancer detection methods, and the growing prevalence of lifestyle and metabolic risk factors in developed countries. However, melanoma mortality rates have generally been decreasing, likely due to advancements in treatment.
Geographic Variation:
There are significant geographic variations in melanoma incidence and mortality. Australia and New Zealand consistently report the highest rates, followed by Western Europe and North America. Melanoma remains rare in most African and Asian countries.
It's important to note that these are estimates, and the true burden of melanoma may vary. Continued research and improved data collection are crucial for a more accurate understanding of melanoma epidemiology and for developing effective prevention and control strategies.
Risk Factors and Comorbidities
The top three risk factors and comorbidities for the occurrence of melanoma are:
-
Ultraviolet (UV) Radiation:
-
UV radiation, primarily from sunlight and tanning beds, is the most significant environmental risk factor for melanoma.
- It is estimated that 60-70% of melanomas are caused by UV radiation.
- UV radiation damages DNA in skin cells, leading to mutations that can cause uncontrolled cell growth and the development of melanoma.
-
Prevention strategies involve minimizing exposure to UV radiation by seeking shade, wearing protective clothing, and using sunscreen with an SPF of 30 or higher.
-
Genetic Susceptibility:
-
Family history of melanoma is a strong risk factor. Individuals with a first-degree relative (parent, sibling, or child) who has had melanoma have a significantly increased risk of developing the disease themselves.
- Specific genes, such as CDKN2A and MC1R, have been linked to an increased risk of melanoma.
-
Genetic testing can be considered for individuals with a strong family history of melanoma to assess their risk.
-
Phenotypic Risk Factors:
-
Certain physical characteristics increase the risk of melanoma. These include:
-
Fair skin: Individuals with fair skin that burns easily and does not tan well are at higher risk.
-
Light-colored eyes (blue or green):
-
Red or blond hair:
-
Large number of moles (nevi): Having more than 50 moles increases the risk of melanoma.
-
Atypical moles (dysplastic nevi): These moles have irregular borders, uneven color, and are larger than normal moles.
-
Personal history of melanoma: Individuals who have had melanoma in the past are at increased risk of developing another melanoma.
- Regular skin self-exams and annual skin checks by a dermatologist are recommended for individuals with these phenotypic risk factors to detect melanoma early.
It is important to note that while these are the top three risk factors, other factors can also contribute to the development of melanoma, such as age, gender, and certain medical conditions. It is crucial to discuss individual risk factors with a healthcare professional.
Recent Studies
Here's a summary of recent melanoma studies, their interventions, and key safety/efficacy outcomes:
- Study: Systematic review and meta-analysis of systemic treatment options for advanced melanoma (2013-2023)
Intervention: BRAF inhibitors (vemurafenib, dabrafenib), MEK inhibitors (trametinib, cobimetinib), and immune checkpoint inhibitors (ipilimumab), including combination therapies.
Efficacy: Combined therapy with vemurafenib, cobimetinib, and ipilimumab showed superior overall survival (OS) and progression-free survival (PFS) compared to monotherapy (OR for OS: 6.95, 95% CI: 4.25-9.64; OR for PFS: 2.49, 95% CI: 1.42-3.56). Dabrafenib and trametinib combination also improved outcomes.
Safety: Vemurafenib was associated with dermatological toxicities. Dabrafenib and trametinib combination showed favorable tolerability and reduced adverse event risk (OR: 2.20, 95% CI: 1.72-2.81).
- Study: Real-world data analysis of advanced melanoma patients in Switzerland.
Intervention: Adjuvant anti-PD1 or BRAF/MEKi for resectable melanoma; anti-PD1, anti-CTLA4/PD1 combination, or BRAF/MEKi for unresectable/metastatic melanoma.
Efficacy: In the resectable setting, 3-year relapse-free survival (RFS) was 53% for anti-PD1 and 67.6% for BRAF/MEKi. In the unresectable setting, 5-year OS was 46.5% for anti-PD1, 52.4% for anti-CTLA4/PD1, and 49.2% for BRAF/MEKi.
Safety: Treatment discontinuation due to toxicity did not affect RFS/OS unless treatment duration was <3 months. Elevated LDH and brain metastases were associated with reduced OS in the unresectable setting.
- Study: Network meta-analysis of targeted therapies for metastatic melanoma.
Intervention: Various targeted therapies, including encorafenib + binimetinib, dabrafenib + trametinib, vemurafenib + cobimetinib, and atezolizumab + vemurafenib + cobimetinib.
Efficacy: Encorafenib + binimetinib showed superiority over dabrafenib + trametinib for overall response rate (ORR) (OR = 1.86; 95% CrI 1.10, 3.17). Atezolizumab + vemurafenib + cobimetinib and encorafenib + binimetinib had comparable efficacy.
Safety: Encorafenib + binimetinib had fewer serious adverse events (SAEs) compared to vemurafenib + cobimetinib (OR = 0.51; 95% CrI 0.29, 0.91) and atezolizumab + vemurafenib + cobimetinib (OR = 0.41; 95% CrI 0.21, 0.82).
- Study: Systematic review and network meta-analysis of melanoma treatments.
Intervention: Chemotherapy, immune checkpoint inhibitors, BRAF/MEK inhibitor therapy, and combinations, including triple therapy (BRAF, MEK, and PD1/PDL1 inhibitors).
Efficacy: Triple therapy showed significantly longer PFS compared to BRAF + MEK combination (HR = 0.76; 95% CI 0.64-0.9), but similar ORR and CRR in BRAF-mutated melanoma.
Safety: Triple therapy had similar SAE and therapy discontinuation rates compared to combined ICI and BRAF/MEK therapies, but more treatment-related adverse events (TRAEs) compared to monotherapies and BRAF/MEK combinations.
- Study: Phase II study of toripalimab in advanced Chinese melanoma patients.
Intervention: Toripalimab 3 mg/kg i.v. every 2 weeks.
Efficacy: ORR of 17.3% and disease control rate (DCR) of 57.5%. Median duration of response was not reached. Median PFS was 3.6 months and median OS was 22.2 months. Patients with positive PD-L1 staining had better ORR, PFS, and OS.
Safety: 90.6% of patients experienced TRAEs, with 19.5% experiencing grade 3 or higher TRAEs.
- Study: Phase II, pivotal registrational study of tunlametinib in unresectable, stage III/IV, NRAS-mutant melanoma.
Intervention: Tunlametinib.
Efficacy: ORR of 35.8%, with a median DOR of 6.1 months. Median PFS was 4.2 months, DCR was 72.6%, and median OS was 13.7 months. In patients with prior immunotherapy, ORR was 40.6%.
Safety: No treatment-related deaths.
These studies highlight the evolving treatment landscape for melanoma, with combination therapies and immunotherapies showing promising efficacy but also potential for adverse events. Biomarkers like PD-L1 status and BRAF mutation status are important for treatment selection and prognostication.
